| Delaware (State or other jurisdiction of | | | 81-5395687 (I.R.S. Employer Identification Number) | |
| Large accelerated filer ☐ | | | Accelerated filer ☐ | |
| Non-accelerated filer ☒ | | | Smaller reporting company ☒ | |
| | | | Emerging growth company ☒ | |
| | | | | 1 | | | |
| | | | | 4 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | ||||
9 | | | ||||||
| | | | | | | ||
| | | | | ||||
| | |||||||
| | | | | | | ||
| | | | | | | ||
| | | | | 16 | | | |
| | | | | 16 | | |
Name of Selling Stockholder | | Shares of Common Stock Beneficially Owned Prior to Offering(1) | | Number of Shares Being Offered | | | Shares of Common Stock Beneficially Owned After Offering(2) | | | Shares of Common Stock Beneficially Owned Prior to Offering(1) | | Number of Shares Being Offered | | | Shares of Common Stock Beneficially Owned After Offering(2) | | ||||||||||||||||||||||||||||||||||
| Number | | Percent | | | Number | | Percent | | |||||||||||||||||||||||||||||||||||||||||
Gilead Sciences, Inc.(3) | | | | 3,759,465 | | | | | 1,666,666 | | | | | 2,092,799 | | | | | 4.11 | | | | | | 18,759,465 | | | | | 15,000,000 | | | | | 3,759,465 | | | | | 3.89% | | |
| SEC registration fee | | | $ | 249.52 | | | SEC registration fee | | | $ | 1,265.86 | | | ||
| Legal fees and expenses | | | | 75,000.00 | | | Legal fees and expenses | | | | 75,000.00 | | | ||
| Accounting fees and expenses(1) | | | | 26,022.50 | | | Accounting fees and expenses(1) | | | | 18,150.00 | | | ||
| Printing and miscellaneous expenses | | | | 7,500.00 | | | Printing and miscellaneous expenses | | | | 7,500.00 | | | ||
| Total | | | $ | 108,772.02 | | | Total | | | $ | 101,915.86 | | |
| |||||
4.3 | | | Registration Rights Agreement, dated June 17, 2022, by and | | |
5.1* | | | | ||
| 23.1* | | | | |
| 23.2* | | | | |
| 24.1* | | | | |
| 107* | | | |
| SIGNATURE | | | TITLE | | | DATE | |
| /s/ Joern Aldag Joern Aldag | | | Chief Executive Officer and Director (Principal Executive Officer) | | | | |
| /s/ Reinhard Kandera Reinhard Kandera | | | Chief Financial Officer and Director (Principal Financial Officer and Principal Accounting Officer) | | | | |
| /s/ Jan van de Winkel, Ph.D. Jan van de Winkel, Ph.D. | | | Chairman of the Board | | | ||
| ||||||||
| /s/ David Kaufman David Kaufman | | | Director | | | | |
| /s/ Julie O’Neill Julie O’Neill | | | Director | | | | |
| /s/ Malte Peters, M.D. Malte Peters, M.D. | | | Director | | | December 22, 2023 | |
| SIGNATURE | | | TITLE | | | DATE | |
| /s/ Timothy Reilly, Ph.D. Timothy Reilly, Ph.D. | | | Director | | | | |
| /s/ Terry Coelho Terry Coelho | | | Director | | | December 22, 2023 | |